RxDoctor Payments Data

Joanne Arbusto, NP

Family · Wappingers Falls, NYNPI 1336373224

Payments from drug & device makers

$2,438in general payments, 2019–2025

Across 147 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$705
  • Scilex Pharmaceuticals Inc.$690
  • Otsuka America Pharmaceutical, Inc.$212
  • Biodelivery Sciences International, Inc.$100
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$95
  • AbbVie$78
  • plus $558 from 19 others

What the payments were for

  • Food & beverage$2,42499%
  • Education$141%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,438 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$69,429
Medicare patients
77
Services billed
1,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate49$35,800
ZtlidoLidocaine31$27,288
OxycontinOxycodone Hcl46$26,149
BelbucaBuprenorphine Hcl26$23,255
Nucynta ErTapentadol Hcl12$12,871
Oxycodone Hcl542$6,674
Lidocaine51$5,437
MovantikNaloxegol Oxalate13$5,131
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen143$4,034
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen226$3,626
Naloxone Hcl53$3,441
Morphine Sulfate ErMorphine Sulfate127$2,489
Pregabalin107$2,331
Fentanyl23$2,211
Methadone Hcl55$1,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er$705$71,92687 claims
Scilex Pharmaceuticals Inc.Ztlido$690$27,28831 claims
Hikma Pharmaceuticals USAMorphine Sulfate$14$32513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in Wappingers Falls

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →